Close

GSK obtains Japanese approval for Encruse Ellipta to treat COPD

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

GlaxoSmithKline (GSK) has obtained Japanese approval for its Encruse Ellipta (umeclidinium).

The Japanese Ministry of Health, Labour and Welfare (MHLW) granted approval for the drug to provide relief from various symptoms due to airway obstruction with chronic obstructive pulmonary diseases (COPD).

Encruse is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator that can improve airflow in and out of the lungs. It is a 62.5mcg strength inhalation powder that can be delivered in the Ellipta inhaler.

GSK global respiratory franchise senior vice-president and head Darrell Baker said: “Encruse is our first LAMA monotherapy and the second treatment from our new COPD portfolio to be approved in Japan within the last year.
“Approval was based on a review of ten Phase III clinical trials, which comprised 4,000 COPD patients treated with umeclidinium or a placebo.”

“The Ellipta inhaler has been positively received by physicians in Japan and today’s approval reflects our goal of providing a range of respiratory medicines in a consistent inhaler that enables physicians to meet the specific needs of individual patients.”

Approval was based on a review of ten Phase III clinical trials, which comprised 4,000 COPD patients treated with umeclidinium or a placebo.

According to GSK, 983 patients received the approved dose of umeclidinium 62.5mcg once-daily in these studies. The company plans to launch the product by the end of 2015 in Japan.

GSK also received MHLW approval for Duac Combination Gel (clindamycin 1%-benzoyl peroxide 3%) to treat acne vulgaris.

In addition, the company obtained approval for pneumococcal conjugate paediatric vaccine Synflorix to treat invasive infectious diseases and pneumonia caused by pneumococcus (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).

Developed by GSK, Synflorix was commercialised by Japan Vaccine, a joint venture of GSK and Daiichi Sankyo.

 

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back